EGUIDE

精神科医療の普及と教育に対するガイドラインの効果に関する研究
～Effectiveness of GUIdeline for Dissemination and Education in psychiatric treatment～

学術論文

  1. *Yamagata H, Fujii Y, Ochi S, Seki T, Hasegawa N, Yamada H, Hori H, Ichihashi K, Iga J, Ogasawara K, Hashimoto N, Iida H, Ohi K, Tsuboi T, Numata S, Hishimoto A, Usami M, Katsumoto E, Muraoka H, Takaesu Y, Nagasawa T, Komatsu H, Miura K, Matsumoto J, Inada K, Nakagawqa S, Hashimoto R. Effect of the guideline education program on anticholinergic and benzodiazepine use in outpatients with schizophrenia and major depressive disorder: The effectiveness of guidelines for Dissemination and education in psychiatric treatment (EGUIDE) project. Psychiatry Research Communications, 4:100158, 2024.2 DOI: 10.1016/j.psycom.2024.100158
    日本語の概要は こちら
  2. Ito S, *Ohi K, Yasuda Y, Fujimoto J, Yamamori H, Matsumoto J, Fukumoto K, Kodaka F, Hasegawa N, Ishimaru K, Miura K, Yasui-Furukori N, Hashimoto R. Better adherence to guidelines among psychiatrists providing pharmacological therapy is associated with longer work hours in patients with schizophrenia. Schizophrenia (Heidelb). 9(1):78, 2023.11 DOI: 10.1038/s41537-023-00407-3
    日本語の概要は こちら
  3. Hasegawa N, Yasuda Y, Yasui-Furukori N, Yamada H, Hori H, Ichihashi K, Takaesu Y, Iida H, Muraoka H, Kodaka F, Iga J, Hashimoto N, Ogasawara K, Ohi K, Fukumoto K, Numata S, Tsuboi T, Usami M, Hishimoto A, Furihata R, Kishimoto T, Nakamura T, Katsumoto E, Ochi S, Nagasawa T, Atake K, Kubota C, Komatsu H, Yamagata H, Ide K Takeshima M, Kido M, Kikuhchi S, Okada T, Matsumoto J, Miura K, Shimaza T, Inada K, Watanabe K, *Hashimoto R. Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study. Psychiatry Clin Neurosci, 77(10):559-568, 2023.10 DOI: 10.1111/pcn.13578
    プレスリリースの内容は こちら
    日本語の概要は こちら
  4. Kodaka F, *Ohi K, Yasuda Y, Fujimoto M, Yamamori H, Hasegawa N, Ito S, Fukumoto K, Matsumoto J, Miura K, Yasui-Furukori N, Hashimoto R. Relationships between Adherence to Guideline Recommendations for Pharmacological Therapy among Clinicians and Psychotic Symptoms in Patients with Schizophrenia. Int J Neuropsychopharmacol, 26(8):557-565, 2023.8 DOI: 10.1093/ijnp/pyad037
    日本語の概要は こちら
  5. Hashimoto N, *Yasui-Furukori N, Hasegawa N, Ishikawa S, Hori H, Iida H, Ichihashi K, Miura K, Matsumoto J, Numata S, Kodaka F, Furihata R, Ohi K, Ogasawara K, Iga JI, Muraoka H, Komatsu H, Takeshima M, Atake K, Kido M, Nakamura T, Kishimoto T, Hishimoto A, Onitsuka T, Okada T, Ochi S, Nagasawa T, Makinodan M, Yamada H, Tsuboi T, Yamada H, Inada K, Watanabe K, Hashimoto R. Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project. BMC Psychiatry, 23(1):473, 2023.6 DOI: 10.1186/s12888-023-04908-4
    日本語の概要は こちら
  6. *Onitsuka T, Okada T, Hasegawa N, Tsuboi T, Iga J, Yaui-Furukori N, Yamada N, Hori H, Muraoka H, Ohi K, Ogasawara K,Ochi S, Takeshima M, Ichihashi K, Fukumoto K, Iida H, Yamada H, Furihata R, Makinodan M, Takaesu Y, Numata S, Komatsu H, HIshimoto A, Kido M, Atake K, Yamagata H, Kikuchi S, Hashimoto N, Usami M, Katsumoto E, Asami T, Kubota C, Matsumoto J, Miura K, Hirano Y, Watanabe K, Inada K, Hashimoto R. Combination psychotropic use for schizophrenia with long-acting injectable antipsychotics and oral antipsychotics: A nationwide real-world study in Japan. J Clin Psychopharmacol, 43(4):365-368, 2023.7/8 DOI: 10.1097/JCP.0000000000001704
    日本語の概要は こちら
  7. Iida H, Okada T, Nemoto K, Hasegawa N, Numata S, Ogasawara K, Miura K, Matsumoto J, Hori H, Iga J, Ichihashi K, Hashimoto N, Yamada H, Ohi K, Yasui-Furukori N, Fukumoto K, Tsuboi T, Usami M, Furihata R, Takaesu Y, Hishimoto A, Muraoka H, Katsumoto E, Nagasawa T, Ochi S, Komatsu H, Kikuchi S, Takeshima M, Onitsuka T, Tamai S, Kubota C, Inada K, Watanabe K, Kawasaki H, *Hashimoto R. Satisfaction with Web-Based Courses on Clinical Practice Guidelines for Psychiatrists: Findings from the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' Project. Neuropsychopharmacol Rep, 43(1):23-32, 2023.3 DOI: 10.1002/npr2.12300
    日本語の概要は こちら
  8. Fukumoto K, Kodaka F, Hasegawa N, Muraoka H, Hori H, Ichihashi K, Yasuda Y, Iida H, Ohi K, Ochi S, Ide K, Hashimoto N, Usami M, Nakamura T, Komatsu H, Okada T, Nagasawa T, Furihata R, Atake K, Kido M, Kikuchi S, Yamagata H, Kishimoto T, Makinodan M, Horai T, Takeshima M, Kubota C, Asami T, Katsumoto E, Hishimoto A, Onitsuka T, Matsumoto J, Miura K, Yamada H, Yasui-Furukori N, Watanabe K, Inada K, Otsuka K, *Hashimoto R. Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders. Neuropsychopharmacol Rep, 43(1):33-39, 2023.3 DOI: 10.1002/npr2.12301
    日本語の概要は こちら
  9. *Tsuboi T, Takaesu Y, Hasegawa N, Ochi S, Fukumoto K, Ohi K, Muraoka H, Okada T, Kodaka F, Igarashi S, Iida H, Kashiwagi H, Hori H, Ichihashi K, Ogasawara K, Hashimoto N, Iga JI, Nakamura T, Usami M, Nagasawa T, Kido M, Komatsu H, Yamagata H, Atake K, Furihata R, Kikuchi S, Horai T, Takeshima M, Hirano Y, Makinodan M, Matsumoto J, Miura K, Hishimoto A, Numata S, Yamada H, Yasui-Furukori N, Inada K, Watanabe K, Hashimoto R. Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysis. Psychiatry Clin Neurosci, 77(1):30-37, 2023.1 DOI: 10.1111/pcn.13489
    日本語の概要は こちら
  10. Kyou Y, *Yasui-Furukori N, Hasegawa N, Ide K, Ichihashi K, Hashimoto N, Hori H, Shimizu Y, Imamura Y, Muraoka H, Iida H, Ohi K, Yasuda Y, Ogasawara K, Numata S, Iga JI, Tsuboi T, Ochi S, Kodaka F, Furihata R, Onitsuka T, Makinodan M, Komatsu H, Takeshima M, Kubota C, Hishimoto A, Atake K, Yamagata H, Kido M, Nagasawa T, Usami M, Kishimoto T, Kikuchi S, Matsumoto J, Miura K, Yamada H, Watanabe K, Inada K, Hahimoto R. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)"project. Ann Gen Psychiatry, 21(1):52, 2022.12 DOI: 10.1186/s12991-022-00429-8
    日本語の概要は こちら
  11. Inada K, Fukumoto K, Hasegawa N, Yasuda Y, Yamada H, Hori H, Ichihashi K,Iida H, Ohi K, Muraoka H, Kodaka F, Ide K, Hashimoto N, Iga JI, Ogasawara K, Atake K, Takaesu Y, Nagasawa T, Komatsu H, Okada T, Furihata R, Kido M, Kikuchi S, Kubota C, Makinodan M, Ochi S, Takeshima M, Yamagata H, Matsumoto J, Miura K, Usami M, Kishimoto T, Onitsuka T, Katsumoto E, Hishimoto A, Numata S, Yasui- Furukori N, Watanabe K, *Hashimoto R. Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia". Neuropsychopharmacol Rep. 42(4):502-509, 2022.12 DOI: 10.1002/npr2.12293
    日本語の概要は こちら
  12. Okada T, *Hori H, Hasegawa N, Murata A, Kyou Y, Kodaka F, Iida H, Ochi S, Takaesu Y, Tsuboi T, Iga JI, Ichihashi K, Muraoka H, Furihata R, Yasui-Furukori N, Usami M, Onitsuka T, Ogasawara K, Tagata H, Takeshima M, Ohi K, Numata S, Hashimoto N, Yamada H, Makinodan M, Komatsu H, Hishimoto A, Yamagata H, Kido M, Kubota C, Atake K, Yamada H, Nagasawa T, Matsumoto J, Miura K, Inada K, Watanabe K, Suda S, Hashimoto R. Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia. J Clin Psychopharmacol, 42(6):591-593, 2022.11 DOI: 10.1097/JCP.0000000000001604
    日本語の概要は こちら
  13. Ochi S, Tagata H, Hasegawa N, *Yasui-Furukori N, Iga JI, Kashiwagi H, Kodaka F, Komatsu H, Tsuboi T, Tokutani A, Numata S, Ichihashi K, Onitsuka T, Muraoka H, Iida H, Ohi K, Atake K, Kishimoto T, Hori H, Takaesu Y, Takeshima M, Usami M, Makinodan M, Hashimoto N, Fujimoto M, Furihata R, Nagasawa T, Yamada H, Matsumoto J, Miura K, Kido M, Hishimoto A, Ueno SI, Watanabe K, Inada K, Hashimoto R. Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study. Int J Neuropsychopharmacol, 25(10):818-826, 2022.10 DOI: 10.1093/ijnp/pyac036
    日本語の概要は こちら
  14. Muraoka H, Kodaka F, Hasegawa N, *Yasui-Furukori N, Fukumoto K, Kashiwagi H, Tagata H, Hori H, Atake K, Iida H, Ichihashi K, Furihata R, Tsuboi T, Takeshima M, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Makinodan M, Nakamura T, Kido M, Ueda I, Yamagata H, Onitsuka T, Asami T, Hishimoto A, Ogasawara K, Katsumoto E, Miura K, Matsumoto J, Ohi K, Yamada H, Watanabe K, Inada K, Nishimura K, Hashimoto R. Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study. Asian J Psychiatr, 74:103174, 2022.8 DOI: 10.1016/j.ajp.2022.103174
    日本語の概要は こちら
  15. *Hori H, Yasui-Furukori N, Hasegawa N, Iga J, Ochi S, Ichihashi K, Furihata R, Kyo Y, Takaesu Y, Tsuboi T, Kodaka F, Onitsuka T, Okada T, Murata A, Kashiwagi H, Iida H, Hashimoto N, Ohi K, Yamada H, Ogasawara K, Yasuda Y, Muraoka H, Usami M, Numata S, Takeshima M, Yamagata H, Nagasawa T, Tagata H, Makinodan M, Kido M, Katsumoto E, Komatsu H, Matsumoto J, Kubota C, Miura K, Hishimoto A, Watanabe K, Inada K, Kawasaki H, Hashimot R. Prescription of anticholinergic drugs in patients with schizophrenia: analysis of antipsychotic prescription patterns and hospital characteristics. Front Psychiatry, section Psychopharmacology, 13:823826, 2022.5 DOI: 10.3389/fpsyt.2022.823826
    日本語の概要は こちら
  16. Yamada H, Motoyama M, Hasegawa N, Miura K, Matsumoto J, Ohi K, Yasui-Furukori N, Numata S, Takeshima M, Sugiyama N, Nagasawa T, Kubota C, Atake K, Tsuboi T, Ichihashi K, Hashimoto N, Inagaki T, Takaesu Y, Iga JI, Hori H, Onitsuka T, Komatsu H, Hishimoto A, Fukumoto K, Fujimoto M, Nakamura T, Nemoto K, Furihata R, Yamamura S, Yamagata H, Ogasawara K, Katsumoto E, Murata A, Iida H, Ochi S, Makinodan M, Kido M, Kishimoto T, Yasuda Y, Usami M, Suwa T, Inada K, Watanabe K, *Hashimoto R. A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. BJPsych Open, 8(3):e83, 2022.4 DOI: 10.1192/bjo.2022.44
    日本語の概要は こちら
  17. Ogasawara K, Numata S, Hasegawa N, Nakataki M, Makinodan M, Ohi K, Takeshima M, Tsuboi T, Hashimoto N, Onitsuka T, Muraoka H, Hori H, Ichihashi K, Inagaki T, Yasui-Furukori N, Hishimoto A, Sugiyama N, Fukumoto K, Nagasawa T, Matsumoto J,Takaesu Y, Furihata R, Nemoto K, Nakamura T, Usami M, Miura K, Fujimoto M,Tagata H, Yamada H, Komatsu H, Ochi S, Atake K, Katsumoto E, Kido M, Kishimoto T, Suwa T, Yamamura S, Iga JI, Iida H, Inada K, Watanabe K, *Hashimoto R. Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacol Rep, 42(2): 221-225, 2022.6 DOI: 10.1002/npr2.12245
    日本語の概要は こちら
  18. Ichihashi K, Kyou Y, Hasegawa N, Yasui-Furukori N, Shimnizu Y, Hori H, Hashimoto N, Ide K, Imamura Y, Yamada H, Ochi S, Iga J, Takaesu Y, Ohi K, Tsuboi T, Iida H, Yamagata H, Hishimoto A, Horai T, Usami M, Makinodan M, Nagasawa T, Komatsu H, Kido M, Muraoka H, Atake K, Takeshima M, Kubota C, Inagaki T, Tamai S, Kishimoto T, Furihata R, Matsumoto J, Miura K, Inada K, Watanabe K, Kasai K, *Hashimoto R. The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. Asian J Psychiatr, 69:103007, 2022.3 DOI:10.1016/j.ajp.2022.103007
    日本語の概要は こちら
  19. Yasui-Furukori N, Muraoka H, Hasegawa N, Ochi S, Numata S, Hori H, Hishimoto A, Onitsuka T, Ohi K, Hashimoto N, Nagasawa T, Takaesu Y, Inagaki T, Tagata H, Tsuboi T, Kubota C, Furihata R, Iga J, Iida H, Miura K, Matsumoto J, Yamada H, Watanabe K, Inada K, Shimoda K, *Hashimoto R. Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep, 42(1):3-9, 2022.3 DOI:10.1002/npr2.12218
    プレスリリースの内容はこちら
  20. Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, Kashiwagi H, Hori H, Ochi S, Muraoka H, Onitsuka T, Komatsu H, Takeshima M, Hishimoto A, Nagasawa T, Takaesu Y, Nakamura T, Asami T, Miura K, Matsumoto J, Ohi K, Yasuda Y, Iida H, Ogasawara K, Hashimoto N, Ichihashi K, Yamada H, Watanabe K, Inada K, *Hashimoto R. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Sleep Med, 89:23-30, 2021.12 DOI:10.1016/j.sleep.2021.11.005
    日本語の概要は こちら
  21. Japanese Society of Neuropsychopharmacology. Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia". Neuropsychopharmacol Rep, 41(3):266-324, 2021.9 DOI:10.1002/npr2.12193
  22. Hashimoto N,*Yasui-Furukori N, Hasegawa N, Ishikawa S, Numata S, Hori H, Iida H, Ichihashi K, Furihata R, Murata A, Tsuboi T, Takeshima M, Kyou Y, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Hishimoto A, Miura K, Matsumoto J, Ohi K, Yamada H, Inada K, Watanabe K, Shimoda K, Hashimoto R. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Asian Journal of Psychiatry, 63:102744, 2021.7 DOI:10.1016/j.ajp.2021.102744
    日本語の概要は こちら
  23. Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K, Matsumoto J, Yasui-Furukori N, Kishimoto T, Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasawa T, Kyou Y, Murata A, Katsumoto E, Ohi K, Hishimoto A, Inada K, Watanabe K, *Hashimoto R. Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep, 41(2):199-206, 2021.6 DOI:10.1002/npr2.12173
    日本語の概要はこちら
  24. Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, Matsumoto J, Murata A, Ogasawara K, Yamada H, Hori H, Ichihashi K, Hashimoto N, Ohi K, Yasui-Furukori N, Tsuboi T, Nakamura T, Usami M, Furihata R, Takaesu Y, Iwamoto K, Sugiyama N, Kishimoto T, Tsujino N, Yamada H, Hishimoto A, Nemoto K, Atake K, Muraoka H, Katsumoto E, Oishi S, Inagaki T, Ito F, Imamura Y, Kido M, Nagasawa T, Numata S, Ochi S, Iwata M, Yamamori H, Fujita J, Onitsuka T, Yamamura S, Makinodan M, Fujimoto M, Takayanagi Y, Takezawa K, Komatsu H, Fukumoto K, Tamai S, Yamagata H, Kubota C, Horai T, Inada K, Watanabe K, Kawasaki H, *Hashimoto R. Unmet need for major depressive disorders-Findings from the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci,74(12):667-669, 2020.12 DOI:10.1111/pcn. 13143
    日本語の概要は こちら
  25. Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, Iwamoto K, Kishimoto T, Horai T, Yamada H, Sugiyama N, Nakamura T, Tsujino N, Nemoto K, Oishi S, Usami M, Katsumoto E, Yamamori H, Tomita H, Suwa T, Furihata R, Inagaki T, Fujita J, Onitsuka T, Miura K, Matsumoto J, Ohi K, Matsui Y, Takaesu Y, Hashimoto N, Iga J, Ogasawara K, Yamada H, Watanabe K, Inada K, *Hashimoto R. Prescription patterns in patients with schizophrenia in Japan: first-quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project. Neuropsychopharmacol Rep, 40(3):281-286, 2020.9 DOI:10.1002/npr2.12122
    日本語の概要はこちら
    →NPPR Article Award 2021を受賞しました。（詳細はこちら）
  26. Takaesu Y, Watanabe K, Numata S, Iwata M, Kudo N, Oishi S, Takizawa T, Nemoto K, Yasuda Y, Tagata H, Tsuboi T, Tsujino N, Hashimoto N, Matsui Y, Hori H, Yamamori H, Sugiyama N, Suwa T, Kishimoto T, Hishimoto A, Usami M, Furihata R, Iwamoto K, Fujishiro H, Nakamura T, Mizuno K, Inagaki T, Katsumoto E, Tomita H, Ohi K, Muraoka H, Atake K, Iida H, Nagasawa T, Fujita J, Yamamura S, Onitsuka T, Murata A, Takayanagi Y, Noda H, Matsumura Y, Takezawa K, Iga J, Ichihashi K, Ogasawara K, Yamada H, Inada K, *Hashimoto R. Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE) ” project: a nationwide dissemination, education and evaluation study. Psychiatry Clin Neurosci, 73(10):642-648, 2019.10 DOI:10.1111/pcn.12911
    プレスリリースの内容は こちら

Copyright c 2018 Department of Pathology of Mental Diseases All Rights Reserved.